Kumquat Biosciences Inc. has described heterocyclic compounds and PROTACs acting as GTPase KRAS (G12D, G12C, G12S and G13D mutant), and/or G12V and wild-type GTPase KRAS inhibitors reported to be useful for the treatment of cancer.
Medshine Discovery Inc. has prepared octahydropyrazinodiazanaphthyridine dione compounds acting as GTPase KRAS inhibitors reported to be useful for the treatment of cancer.
Incyte Corp. has disclosed GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, inflammatory and immunological disorders.
Nikang Therapeutics Inc. and Shanghai Blueray Biopharma Co. Ltd. have described exocyclic amino quinazoline derivatives acting as GTPase KRAS inhibitors, particularly KRAS (G12D mutant) inhibitors, reported to be useful for the treatment of cancer.
